drugset
drugset / Trial / NCT06604624

Semaglutide in Treatment of Obesity

NCT06604624 ↗

Phase 3 Completed 462 enrolled CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

Timeline

Start
2024-09-20
Primary completion
2025-08-27
Completion
2025-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject HD1916 Unknown 0.25 mg Subcutaneous
Subject HD1916 Unknown 0.5 mg Subcutaneous
Subject HD1916 Unknown 1 mg Subcutaneous
Subject HD1916 Unknown 1.7 mg Subcutaneous
Subject HD1916 Unknown 2.4 mg Subcutaneous
Comparator Semaglutide Peptide 0.25 mg Subcutaneous
Comparator Semaglutide Peptide 0.5 mg Subcutaneous
Comparator Semaglutide Peptide 1 mg Subcutaneous
Comparator Semaglutide Peptide 1.7 mg Subcutaneous
Comparator Semaglutide Peptide 2.4 mg Subcutaneous

Indications

No indication recorded.